In addition, the ability of the selective COX-2 inhibitor celecoxib to prevent IDO activation and thereby enhancing an anti-tumor vaccination strategy has been reported in a mammary as well as in pancreatic carcinoma mouse model [73,74,75]. Here, IDO1 is linked to exocrine pancreatic carcinoma.